In the September 2025 quarter, Biocons generics business grew 24% year-on-year to 774 crore, with margins on its biosimilars near-copies of complex biological drugs expanding to 28% at the operating-profit (EBITDA) level
This includes discussing all treatment options, possibly welcoming further advice from other medical professionals, explaining hospital procedures, recovery and time off work
h , Co-IP assays showing there were no interactions between IDH1mt 3CS and Zdhhc7, 9, 14 or 23
It's possible that AOD9604 may influence the fat cells and lipolytic receptors, particularly given its observed association with changes in weight and fat in murine models
Pharmacological properties and derivatives of shikonin-a review in recent years
10.1007/s40618-017-0792-x 89 KimY.YooS.LimB.HongJ